XON - Intrexon Corporation
| Previous Close | 5.69 |
| Open | 5.69 |
| Bid | 5.87 x 4000 |
| Ask | 5.88 x 1800 |
| Day's Range | 5.64 - 5.92 |
| 52 Week Range | 3.95 - 9.10 |
| Volume | 198,654 |
| Avg. Volume | 988,065 |
| Market Cap | 958M |
| Beta (3Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.33 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
- Benzinga
12 Biotech Stocks Primed For A Short Squeeze
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
- PR Newswire
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
GERMANTOWN, Md. , Nov. 18, 2019 /PRNewswire/ -- Triple-Gene LLC , a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday presented ...
- Benzinga
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Biotech stocks went about a consolidation move last week, although a few swung wildly in either direction in reaction to some catalytic events. Aslan (NASDAQ: ASLN ) tumbled after its late-stage biliary ...
- Zacks
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the third quarter of 2019.
- PR Newswire
Intrexon Reports Third Quarter 2019 Financial Results
- Tightened focus on healthcare and on track to meet yearend transactional and cash goals - - Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon of $53.6 million including non-cash ...
- PR Newswire
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
- Company to Present Preliminary Data at American Heart Association Scientific Sessions - GERMANTOWN, Md. , Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC , a clinical stage cardiovascular gene therapy company ...
- PR Newswire
Intrexon to Announce Third Quarter Financial Results on November 12th
- Intrexon's subsidiary Precigen to host conference call to provide business and pipeline updates - GERMANTOWN, Md. , Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering ...
- Insider Monkey
Is Intrexon Corp (XON) Going To Burn These Hedge Funds ?
Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]
- Simply Wall St.
Have Insiders Been Selling Intrexon Corporation (NASDAQ:XON) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- PR Newswire
David H. Witte to lead MBP Titan LLC
- Former head of IHS Markit Energy, Chemicals and Agribusiness Division to lead company for Intrexon's Methane Bioconversion Platform (MBP) - GERMANTOWN, Md., Sept. 26, 2019 /PRNewswire/ -- Intrexon Corporation ...
- GlobeNewswire
Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet Production
Next Green Wave Holdings Inc. (CSE: NGW) (NXGWF) ("Next Green Wave", “NGW” or the "Company") announces that it has completed the installation and activation of its research and innovation laboratory under license from biotech leader Intrexon (XON).
- Zacks
Teladoc Gains on Growing Acceptance for TeleHealth Services
Teladoc's (TDOC) extensive ecosystem and infrastructure poise it well for long-term growth in the expanding telehealth industry.
- PR Newswire
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
GHENT, Belgium, Aug. 19, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017, an innovative orally-delivered therapeutic candidate for the treatment of celiac disease. ActoBio Therapeutics™ is dedicated to developing and commercializing the next generation of oral antigen-specific immunotherapy utilizing its proprietary delivery vehicle.
- Simply Wall St.
Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77%
Intrexon Corporation (NASDAQ:XON) shareholders will doubtless be very grateful to see the share price up 46% in the...
- Thomson Reuters StreetEvents
Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT
Q2 2019 Intrexon Corp Earnings Call
Motley FoolIntrexon Corp (XON) Q2 2019 Earnings Call Transcript
XON earnings call for the period ending June 30, 2019.
- Zacks
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
- PR Newswire
Intrexon Reports Second Quarter and First Half 2019 Financial Results
- Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million - GERMANTOWN, Md. , Aug. 8, 2019 /PRNewswire/ -- Intrexon Corporation ...
- PR Newswire
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors - First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ...
- Zacks
Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline
Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th
GERMANTOWN, Md. , Aug. 1, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
- Motley Fool
Here's Why Intrexon Jumped 58% in June
The biotech is getting into the cannabinoids business.
- Simply Wall St.
What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It?
Intrexon Corporation (NASDAQ:XON) is a small-cap stock with a market capitalization of US$1.2b. While investors...
- PR Newswire
ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
GHENT, Belgium, July 1, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will progress to the next stage of the Phase Ib/IIa clinical trial for investigational drug AG019 for the treatment of early-onset type 1 diabetes (T1D). This follows a scheduled review by the independent Data and Safety Monitoring Board, which supported moving forward with the study.
- PR Newswire
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
GERMANTOWN, Md., June 26, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform. PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell therapy under investigation for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) (clinical trial identifier: NCT03927261).
